Apollomics, Inc.

AI-generated fair value estimate for this company.

Method: Sum-of-the-parts, risk-adjusted rNPV: pro forma net cash of about $14.4M after recent financing; risk-adjusted NPV of the China royalty/licensing stream for vebreltinib (APL-101), assuming it scales toward about $12M per year by 2029 with roughly 30% probability-weighting for continued commercial execution and potential ex-China licensing, discounted at 20% WACC with an 8x terminal multiple, contributing about $40M; total equity value of about $55M divided by approximately 2.2M diluted shares (post 1-for-100 reverse split).

Reasoning: As a commercial-stage-in-China but still cash-constrained, loss-making biopharma with one approved but early-commercialization asset, a full DCF is premature; an rNPV/sum-of-parts approach blending hard cash with probability-weighted licensing economics better captures both the real approval catalyst and the going-concern-level cash risk.